ESSA Pharma (EPIX) shares were down more than 65% premarket Friday after the company said it decided to terminate the phase 2 trial evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.
The company said in a Thursday statement that the trial is unlikely to achieve the primary endpoint as interim data showed that "there was no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent."
The study's primary endpoint is the proportion of patients reaching a PSA90 response and ESSA Pharma said trial data showed a "much higher" rate of PSA90 response in patients treated with enzalutamide monotherapy.
Price: 1.81, Change: -3.39, Percent Change: -65.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。